(UroToday.com) Patients undergoing radical surgery for muscle-invasive urothelial carcinoma face a high risk of disease recurrence. Recurrence is associated with worse survival, but its effect on health-related quality of life (HRQoL) is unclear. In the ongoing phase 3 CheckMate 274 trial, adjuvant nivolumab monotherapy significantly improved disease-free survival in patients with muscle-invasive urothelial carcinoma who had undergone radical resection surgery. At the 2021 America Society of Clinical Oncology (ASCO) virtual annual meeting, Dr. Matt Galsky and colleagues presented results of a post hoc analysis assessing the impact of recurrence on HRQoL using data from the phase 3 CheckMate 274 trial.